drug
midazolam
Marketedupdated 5mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Epilepsy
all catalysts(0)
nothing on the calendar yet
Trials studying midazolam
- phase1A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
- phase1An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
- phase1An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
- phase1A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- phase1A Trial of Lu AH69593 in Healthy Participants
- phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
- phase1FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 18, 2028
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 20, 2038formulationUS 10966990
- Jun 20, 2038formulationUS 10966990
- Jan 18, 2028formulationUS 82170331.3y
- Jan 18, 2028formulationUS 88093221.3y
- Jan 18, 2028formulationUS 92894321.3y
- Jan 18, 2028formulationUS 96874951.3y
FDA exclusivities (1)
- May 17, 2026ODE-243Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that